The Tumor-Necrosis-Factor alpha (TNF-a) blockers are biologic medications that have shown great promise in treating ankylosing spondylitis. They have been shown to be highly effective in treating not only the arthritis of the joints but the spinal arthritis associated with ankylosing spondylitis and related diseases.

This study looked at the effectiveness of switching between TNF-a medications to see if one would work when another had not.

The authors conclude that, “In the event of failure or intolerance to anti-TNF-a in the treatment of [spondyloarthropathies], performing a first or second switch produces a satisfactory therapeutic response.

via Press – News – 462 – Efficacy in current practice of switching between anti-tumour necrosis factor-a agents in spondyloarthropathies.